Trial Profile
Pilot Trial Evaluating Viral Protein Production From the Combination of Reolysin and Carfilzomib in Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Sep 2023
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Pelareorep (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Proof of concept
- 28 Jan 2023 Planned End Date changed from 23 Nov 2022 to 23 Nov 2023.
- 24 Nov 2021 Status changed from recruiting to active, no longer recruiting.
- 10 Feb 2021 Planned primary completion date changed from 31 Dec 2020 to 26 Oct 2021.